Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Piekarz, R. L.
Right arrow Articles by Bates, S. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Piekarz, R. L.
Right arrow Articles by Bates, S. E.
Related Collections
Right arrow Gene Expression
Right arrow Brief Reports
Right arrow Clinical Trials and Observations
Right arrow Neoplasia
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

arrow to previous article Previous Article  |  Table of Contents  |  Next Article next article arrow

Blood, 1 November 2001, Vol. 98, No. 9, pp. 2865-2868

BRIEF REPORT

Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report

Richard L. Piekarz, Rob Robey, Victor Sandor, Susan Bakke, Wyndham H. Wilson, Laila Dahmoush, Douglas M. Kingma, Maria L. Turner, Rosemary Altemus, and Susan E. Bates

From the Medicine Branch, the Laboratory of Pathology, the Dermatology Branch, and the Radiation Oncology Branch of the Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD.

Depsipeptide, FR901228, has demonstrated potent in vitro and in vivo cytotoxic activity against murine and human tumor cell lines. In the laboratory, it has been shown to be a histone deacetylase (HDAC) inhibitor. In a phase I trial of depsipeptide conducted at the National Cancer Institute, 3 patients with cutaneous T-cell lymphoma had a partial response, and 1 patient with peripheral T-cell lymphoma, unspecified, had a complete response. Sézary cells isolated from patients after treatment had increased histone acetylation. These results suggest that inhibition of HDAC is a novel and potentially effective therapy for patients with T-cell lymphoma.

© 2001 by The American Society of Hematology.
 

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
L. Ellis, Y. Pan, G. K. Smyth, D. J. George, C. McCormack, R. Williams-Truax, M. Mita, J. Beck, H. Burris, G. Ryan, et al.
Histone Deacetylase Inhibitor Panobinostat Induces Clinical Responses with Associated Alterations in Gene Expression Profiles in Cutaneous T-Cell Lymphoma
Clin. Cancer Res., July 15, 2008; 14(14): 4500 - 4510.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
M. Crump, B. Coiffier, E. D. Jacobsen, L. Sun, J. L. Ricker, H. Xie, S. R. Frankel, S. S. Randolph, and B. D. Cheson
Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid) in relapsed diffuse large-B-cell lymphoma
Ann. Onc., May 1, 2008; 19(5): 964 - 969.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
L. L. Siu, R. Pili, I. Duran, W. A. Messersmith, E. X. Chen, R. Sullivan, M. MacLean, S. King, S. Brown, G. K. Reid, et al.
Phase I Study of MGCD0103 Given As a Three-Times-Per-Week Oral Dose in Patients With Advanced Solid Tumors
J. Clin. Oncol., April 20, 2008; 26(12): 1940 - 1947.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
Y. Dai, S. Chen, L. B. Kramer, V. L. Funk, P. Dent, and S. Grant
Interactions between Bortezomib and Romidepsin and Belinostat in Chronic Lymphocytic Leukemia Cells
Clin. Cancer Res., January 15, 2008; 14(2): 549 - 558.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
P. P. Piccaluga, C. Agostinelli, A. Califano, A. Carbone, L. Fantoni, S. Ferrari, A. Gazzola, A. Gloghini, S. Righi, M. Rossi, et al.
Gene Expression Analysis of Angioimmunoblastic Lymphoma Indicates Derivation from T Follicular Helper Cells and Vascular Endothelial Growth Factor Deregulation
Cancer Res., November 15, 2007; 67(22): 10703 - 10710.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. Zimmermann, F. Kiefer, M. Prudenziati, C. Spiller, J. Hansen, T. Floss, W. Wurst, S. Minucci, and M. Gottlicher
Reduced Body Size and Decreased Intestinal Tumor Rates in HDAC2-Mutant Mice
Cancer Res., October 1, 2007; 67(19): 9047 - 9054.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
B. S. Mann, J. R. Johnson, M. H. Cohen, R. Justice, and R. Pazdur
FDA Approval Summary: Vorinostat for Treatment of Advanced Primary Cutaneous T-Cell Lymphoma
Oncologist, October 1, 2007; 12(10): 1247 - 1252.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
E. L. Strevel, D. J. Ing, and L. L. Siu
Molecularly Targeted Oncology Therapeutics and Prolongation of the QT Interval
J. Clin. Oncol., August 1, 2007; 25(22): 3362 - 3371.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
N. Keshelava, E. Davicioni, Z. Wan, L. Ji, R. Sposto, T. J. Triche, and C. P. Reynolds
Histone Deacetylase 1 Gene Expression and Sensitization of Multidrug-Resistant Neuroblastoma Cell Lines to Cytotoxic Agents by Depsipeptide
J Natl Cancer Inst, July 18, 2007; 99(14): 1107 - 1119.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. Nencioni, J. Beck, D. Werth, F. Grunebach, F. Patrone, A. Ballestrero, and P. Brossart
Histone Deacetylase Inhibitors Affect Dendritic Cell Differentiation and Immunogenicity
Clin. Cancer Res., July 1, 2007; 13(13): 3933 - 3941.
[Abstract] [Full Text] [PDF]

Home page
 Appl. Environ. Microbiol.Home page
Y.-Q. Cheng, M. Yang, and A. M. Matter
Characterization of a Gene Cluster Responsible for the Biosynthesis of Anticancer Agent FK228 in Chromobacterium violaceum No. 968
Appl. Envir. Microbiol., June 1, 2007; 73(11): 3460 - 3469.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
M. E. Goldsmith, A. Aguila, K. Steadman, A. Martinez, S. M. Steinberg, M. C. Alley, W. R. Waud, S. E. Bates, and T. Fojo
The histone deacetylase inhibitor FK228 given prior to adenovirus infection can boost infection in melanoma xenograft model systems
Mol. Cancer Ther., February 1, 2007; 6(2): 496 - 505.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
B. Sanchez-Gonzalez, H. Yang, C. Bueso-Ramos, K. Hoshino, A. Quintas-Cardama, V. M. Richon, and G. Garcia-Manero
Antileukemia activity of the combination of an anthracycline with a histone deacetylase inhibitor
Blood, August 15, 2006; 108(4): 1174 - 1182.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. Fouladi, W. L. Furman, T. Chin, B. B. Freeman III, L. Dudkin, C. F. Stewart, M. D. Krailo, R. Speights, A. M. Ingle, P. J. Houghton, et al.
Phase I Study of Depsipeptide in Pediatric Patients With Refractory Solid Tumors: A Children's Oncology Group Report
J. Clin. Oncol., August 1, 2006; 24(22): 3678 - 3685.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. E. Bates, D. R. Rosing, T. Fojo, and R. L. Piekarz
Challenges of Evaluating the Cardiac Effects of Anticancer Agents.
Clin. Cancer Res., July 1, 2006; 12(13): 3871 - 3874.
[Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. H. Shah, P. Binkley, K. Chan, J. Xiao, D. Arbogast, M. Collamore, Y. Farra, D. Young, and M. Grever
Cardiotoxicity of Histone Deacetylase Inhibitor Depsipeptide in Patients with Metastatic Neuroendocrine Tumors.
Clin. Cancer Res., July 1, 2006; 12(13): 3997 - 4003.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. L. Piekarz, A. R. Frye, J. J. Wright, S. M. Steinberg, D. J. Liewehr, D. R. Rosing, V. Sachdev, T. Fojo, and S. E. Bates
Cardiac Studies in Patients Treated with Depsipeptide, FK228, in a Phase II Trial for T-Cell Lymphoma.
Clin. Cancer Res., June 15, 2006; 12(12): 3762 - 3773.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
B. Heltweg, T. Gatbonton, A. D. Schuler, J. Posakony, H. Li, S. Goehle, R. Kollipara, R. A. DePinho, Y. Gu, J. A. Simon, et al.
Antitumor activity of a small-molecule inhibitor of human silent information regulator 2 enzymes.
Cancer Res., April 15, 2006; 66(8): 4368 - 4377.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. W. Robey, Z. Zhan, R. L. Piekarz, G. L. Kayastha, T. Fojo, and S. E. Bates
Increased MDR1 Expression in Normal and Malignant Peripheral Blood Mononuclear Cells Obtained from Patients Receiving Depsipeptide (FR901228, FK228, NSC630176)
Clin. Cancer Res., March 1, 2006; 12(5): 1547 - 1555.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
M. A. Rizvi, A. M. Evens, M. S. Tallman, B. P. Nelson, and S. T. Rosen
T-cell non-Hodgkin lymphoma
Blood, February 15, 2006; 107(4): 1255 - 1264.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
O. A. O'Connor, M. L. Heaney, L. Schwartz, S. Richardson, R. Willim, B. MacGregor-Cortelli, T. Curly, C. Moskowitz, C. Portlock, S. Horwitz, et al.
Clinical Experience With Intravenous and Oral Formulations of the Novel Histone Deacetylase Inhibitor Suberoylanilide Hydroxamic Acid in Patients With Advanced Hematologic Malignancies
J. Clin. Oncol., January 1, 2006; 24(1): 166 - 173.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
N. Gao, M. Rahmani, X. Shi, P. Dent, and S. Grant
Synergistic antileukemic interactions between 2-medroxyestradiol (2-ME) and histone deacetylase inhibitors involve Akt down-regulation and oxidative stress
Blood, January 1, 2006; 107(1): 241 - 249.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
M. R. Acharya, A. Sparreboom, J. Venitz, and W. D. Figg
Rational Development of Histone Deacetylase Inhibitors as Anticancer Agents: A Review
Mol. Pharmacol., October 1, 2005; 68(4): 917 - 932.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
O. A. O'Connor
Targeting Histones and Proteasomes: New Strategies for the Treatment of Lymphoma
J. Clin. Oncol., September 10, 2005; 23(26): 6429 - 6436.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
R. van Doorn, W. H. Zoutman, R. Dijkman, R. X. de Menezes, S. Commandeur, A. A. Mulder, P. A. van der Velden, M. H. Vermeer, R. Willemze, P. S. Yan, et al.
Epigenetic Profiling of Cutaneous T-Cell Lymphoma: Promoter Hypermethylation of Multiple Tumor Suppressor Genes Including BCL7a, PTPRG, and p73
J. Clin. Oncol., June 10, 2005; 23(17): 3886 - 3896.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
Y. Xiong, S. C. Dowdy, K. C. Podratz, F. Jin, J. R. Attewell, N. L. Eberhardt, and S.-W. Jiang
Histone Deacetylase Inhibitors Decrease DNA Methyltransferase-3B Messenger RNA Stability and Down-regulate De novo DNA Methyltransferase Activity in Human Endometrial Cells
Cancer Res., April 1, 2005; 65(7): 2684 - 2689.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
J. C. Byrd, G. Marcucci, M. R. Parthun, J. J. Xiao, R. B. Klisovic, M. Moran, T. S. Lin, S. Liu, A. R. Sklenar, M. E. Davis, et al.
A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia
Blood, February 1, 2005; 105(3): 959 - 967.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
P. M. Das and R. Singal
DNA Methylation and Cancer
J. Clin. Oncol., November 15, 2004; 22(22): 4632 - 4642.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
S. Doi, H. Soda, M. Oka, J. Tsurutani, T. Kitazaki, Y. Nakamura, M. Fukuda, Y. Yamada, S. Kamihira, and S. Kohno
The histone deacetylase inhibitor FR901228 induces caspase-dependent apoptosis via the mitochondrial pathway in small cell lung cancer cells
Mol. Cancer Ther., November 1, 2004; 3(11): 1397 - 1402.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
S. Roychowdhury, R. A. Baiocchi, S. Vourganti, D. Bhatt, B. W. Blaser, A. G. Freud, J. Chou, C.-S. Chen, J. J. Xiao, M. Parthun, et al.
Selective Efficacy of Depsipeptide in a Xenograft Model of Epstein-Barr Virus-Positive Lymphoproliferative Disorder
J Natl Cancer Inst, October 6, 2004; 96(19): 1447 - 1457.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
K. J. Savage, M. Chhanabhai, R. D. Gascoyne, and J. M. Connors
Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification
Ann. Onc., October 1, 2004; 15(10): 1467 - 1475.
[Abstract] [Full Text] [PDF]

Home page
 CA Cancer J ClinHome page
B. D. Cheson
What Is New in Lymphoma?
CA Cancer J Clin, September 1, 2004; 54(5): 260 - 272.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
L. A. Wolfraim, T. M. Fernandez, M. Mamura, W. L. Fuller, R. Kumar, D. E. Cole, S. Byfield, A. Felici, K. C. Flanders, T. M. Walz, et al.
Loss of Smad3 in Acute T-Cell Lymphoblastic Leukemia
N. Engl. J. Med., August 5, 2004; 351(6): 552 - 559.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
R. L. Piekarz, R. W. Robey, Z. Zhan, G. Kayastha, A. Sayah, A. H. Abdeldaim, S. Torrico, and S. E. Bates
T-cell lymphoma as a model for the use of histone deacetylase inhibitors in cancer therapy: impact of depsipeptide on molecular markers, therapeutic targets, and mechanisms of resistance
Blood, June 15, 2004; 103(12): 4636 - 4643.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. Adachi, Y. Zhang, X. Zhao, T. Minami, R. Kawamura, Y. Hinoda, and K. Imai
Synergistic Effect of Histone Deacetylase Inhibitors FK228 and m-Carboxycinnamic Acid Bis-Hydroxamide with Proteasome Inhibitors PSI and PS-341 against Gastrointestinal Adenocarcinoma Cells
Clin. Cancer Res., June 1, 2004; 10(11): 3853 - 3862.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
N. Mori, T. Matsuda, M. Tadano, T. Kinjo, Y. Yamada, K. Tsukasaki, S. Ikeda, Y. Yamasaki, Y. Tanaka, T. Ohta, et al.
Apoptosis Induced by the Histone Deacetylase Inhibitor FR901228 in Human T-Cell Leukemia Virus Type 1-Infected T-Cell Lines and Primary Adult T-Cell Leukemia Cells
J. Virol., May 1, 2004; 78(9): 4582 - 4590.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. Rahmani, C. Yu, Y. Dai, E. Reese, W. Ahmed, P. Dent, and S. Grant
Coadministration of the Heat Shock Protein 90 Antagonist 17-Allylamino- 17-demethoxygeldanamycin with Suberoylanilide Hydroxamic Acid or Sodium Butyrate Synergistically Induces Apoptosis in Human Leukemia Cells
Cancer Res., December 1, 2003; 63(23): 8420 - 8427.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. E. Goldsmith, M. Kitazono, P. Fok, T. Aikou, S. Bates, and T. Fojo
The Histone Deacetylase Inhibitor FK228 Preferentially Enhances Adenovirus Transgene Expression in Malignant Cells
Clin. Cancer Res., November 1, 2003; 9(14): 5394 - 5401.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
L. Catley, E. Weisberg, Y.-T. Tai, P. Atadja, S. Remiszewski, T. Hideshima, N. Mitsiades, R. Shringarpure, R. LeBlanc, D. Chauhan, et al.
NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma
Blood, October 1, 2003; 102(7): 2615 - 2622.
[Abstract] [Full Text] [PDF]

Home page
 IOVSHome page
D. D. Klisovic, S. E. Katz, D. Effron, M. I. Klisovic, J. Wickham, M. R. Parthun, M. Guimond, and G. Marcucci
Depsipeptide (FR901228) Inhibits Proliferation and Induces Apoptosis in Primary and Metastatic Human Uveal Melanoma Cell Lines
Invest. Ophthalmol. Vis. Sci., June 1, 2003; 44(6): 2390 - 2398.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
Md. M. Rahman, A. Kukita, T. Kukita, T. Shobuike, T. Nakamura, and O. Kohashi
Two histone deacetylase inhibitors, trichostatin A and sodium butyrate, suppress differentiation into osteoclasts but not into macrophages
Blood,